A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus Clinical Trial

Official title:

A Randomized, Single-centre, Double-blind, 2-period Cross-over Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03981627
• Other study ID #: CT038-ADO09
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: June 6, 2019
• Est. completion date: June 27, 2020

Study information

• Verified date: November 2020
• Source: Adocia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, active-controlled, 2 period cross-over clinical trial in subjects with type 1 diabetes mellitus using a Multiple Daily Injection (MDI) regimen.

Description:

After a screening visit, eligible subjects will enter a run-in period. Subjects will receive a Continuous Glucose Monitoring (CGM) system for glucose monitoring and control at the beginning of the run-in and for the whole duration of the study. Each eligible subject will then be randomly allocated to a sequence of the 2 treatments, i.e. multiple daily injections of ADO09 and insulin aspart during 2 dosing periods. At Day 1 a mixed meal test (MMT) will be conducted at breakfast and subjects will remain at the clinical site until day 3. At Day 3 subjects will leave the clinical site and continue the treatment with IMP for the next 3 weeks. On Day 23 subjects will come back for a MMT on Day 24.

This study is constituted of 2 parts. In the first part (Part A), only subjects with daily prandial insulin dose ≤ 40 U/day will be enrolled.

Following the completion of the part A, an extension part (Part B) will be conducted to particularly assess the safety and tolerability of higher daily doses of ADO09 in patients with insulin requirements ≥ 40 U/day.

The clinical conduct and procedures will not change for the Extension Part of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: June 27, 2020
• Est. primary completion date: June 27, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Signed and dated informed consent obtained before any trial-related activities.

• Type 1 diabetes mellitus (as diagnosed clinically) = 12 months.

• Treated with insulin = 12 months.

• Using a multiple dosing insulin therapy (MDI) with basal and bolus insulin.

• HbA1c = 9.0%.

• Fasting negative C-peptide (= 0.30 nmol/L).

• Total daily prandial dose: = 40U in the Part A and = 40 U in the Part B

Exclusion Criteria:

• Known or suspected hypersensitivity to products used in the clinical trial

• Type 2 diabetes mellitus

• Previous participation in this trial. Participation is defined as randomized.

• Receipt of any medicinal product in clinical development within 3 months before randomization in this trial.

• Known slowing of gastric emptying, including gastroparesis, and or gastrointestinal surgery that in the opinion of the investigator might change gastrointestinal motility and food absorption.

• Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea), as judged by the Investigator.

• Intake of medication known to affect gastrointestinal motility, including but not limited to erythromycin, metoclopramide, cisapride, cholestyramine or colestipol within 4 weeks before screening.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes Mellitus

Intervention

Drug:
• ADO09 formulation
Subcutaneous injection of ADO09 formulation
• NovoRapid®
Subcutaneous injection of insulin aspart

Locations

Country	Name	City	State
Germany	Profil Institut für Stoffwechselforschung GmbH	Neuss

Sponsors (1)

Lead Sponsor	Collaborator
Adocia

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	?AUCPG(0-4h)	Incremental area under the plasma glucose concentration-time curve from 0-4 hours after start of breakfast, assessed by Super GL at day 24.	From 0 to 4 hours
Secondary	Pharmacokinetics of pramlintide	Area under the pramlintide concentration-time curve	From 0 to 4 hours
Secondary	Pharmacokinetics of insulins	Area under the insulins concentration-time curve	From 0 to 4 hours
Secondary	Plasma glucose control as measured by CGM	Time and percentage of time in Range (TiR) [70-180] mg/dL	Over 24 hours
Secondary	Safety and tolerability (Adverse Events recording)	Number of Adverse Events	Up to 24 days